DiaSpect Medical, EKF Diagnostics, Selah Genomics deal

Diagnostic company EKF acquired Selah Genomics and DiaSpect Medical in cash and stock deals that value Selah at up to $68.1 million and DiaSpect at up to $34.6 million, based on EKF's close of 35p on April 21, the day before EKF announced the deal close. Selah received 58.4 million shares of EKF and is eligible for up $35 million in shares of EKF contingent on revenue targets. DiaSpect received £10.2 million ($17.2 million) in cash up front as well as 15.9 million shares of EKF. The company is also eligible for up to £4.8 million ($8 million) in milestones. ...